Lauren B. Banks

Oncology

160 E 53rd St
New York, NY 10022

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Natural history and treatment outcomes in aggressive angiomyxoma: A single institution experience.

Natural history and treatment outcomes in aggressive angiomyxoma: A single institution experience.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 27, 2026

Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma.

Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma.

Journal: Journal for immunotherapy of cancer

Published: April 15, 2026

Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II Trials.

Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II Trials.

Journal: Cancer medicine

Published: April 08, 2026

Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma.

Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 10, 2025

Future Directions and Priorities for Cellular Therapy in Sarcoma: A Report from the Strategic Advances in Sarcoma Science Cell Therapy Breakout.

Future Directions and Priorities for Cellular Therapy in Sarcoma: A Report from the Strategic Advances in Sarcoma Science Cell Therapy Breakout.

Journal: Cancers

Published: August 19, 2025

High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy.

High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: July 16, 2025

Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma.

Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma.

Journal: Cancer research communications

Published: June 25, 2025

Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma.

Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma.

Journal: Journal for immunotherapy of cancer

Published: May 28, 2025

ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor.

ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 16, 2025

Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma.

Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 05, 2024

Akt2 deficiency impairs Th17 differentiation, augments Th2 differentiation, and alters the peripheral response to immunization.

Akt2 deficiency impairs Th17 differentiation, augments Th2 differentiation, and alters the peripheral response to immunization.

Journal: bioRxiv : the preprint server for biology

Published: June 25, 2024

Team Approach: Extremity Soft Tissue Sarcoma.

Team Approach: Extremity Soft Tissue Sarcoma.

Journal: JBJS reviews

Published: December 20, 2023

Showing 1-12 of 18

Last Updated: 09/26/2026